Lomustine and bevacizumab in progressive glioblastoma

A research team with members from Belgium, the Netherlands, France, and Switzerland investigated lomustine bevacizumab vs. lomustine alone for the treatment of progressive glioblastoma.

A research team with members from Belgium, the Netherlands, France, and Switzerland investigated lomustine bevacizumab vs. lomustine alone for the treatment of progressive glioblastoma. The trial involved 437 patients whose disease continued to advance despite chemotherapy, 288 of them randomized to combination therapy and 149 assigned to monotherapy. The researchers found, however, that adding bevacizumab to lomustine did not provide a significant survival benefit in this population. Patients in that treatment arm achieved median overall survival of 8.1 months compared with 8.6 months for lomustine-only patients. Progression-free survival, meanwhile, was greater with bevacizumab lomustine—at 4.2 months vs. 1.5 months—but combination therapy also was associated with nearly twice as many grade 3 to 5 adverse events.